Refractory invasive pulmonary aspergillosis
Conditions
Interventions
Conventional Treatment Group:Conventional antifungal therapy
Experimental group:In addition to standard antifungal therapy, administer local intralesional antifungal agent L-AmB through a bronchial catheter guided by bronchoscopy
Sponsors
Shanxi Bethune Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age 18 years or older; 2.Patients with refractory invasive pulmonary aspergillosis and mucormycosis(refer to the expert consensus on the diagnostic pathway of invasive pulmonary fungal disease (2024 Edition);
Exclusion criteria
Exclusion criteria: 1.Expected survival time less than 3 months; 2.History of allergy to amphotericin B; 3.Bleeding tendency or other contraindications to bronchoscopy; 4.Moderate to severe liver disease; 5.Renal insufficiency or failure; 6.Hemodynamic instability; 7.Severe immunodeficiency; 8.Patients of reproductive age who are trying to conceive, pregnant, or breastfeeding; 9.Poor adherence or patients with psychiatric disorders;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imaging Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety Assessment;Clinical response rate; | — |
Countries
China
Contacts
Public ContactLi Xiaochen
Shanxi Bethune Hospital
Outcome results
None listed